Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | PKM | P14618 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3579896 | 0.89 | HRH4 (0.44) | ALDH1A1PKMKMT2ALMNAMEN1 | |
| SCHEMBL25259362 | 0.84 | ALDH1A1 (0.48) | ALDH1A1PKMKMT2ALMNAMEN1 | |
| SCHEMBL588563 | 0.78 | RAB9A (0.62) | ALDH1A1PKMKMT2ALMNAMEN1 | |
| SCHEMBL25598188 | 0.77 | ALDH1A1 (0.66) | ALDH1A1PKMKMT2ALMNAMEN1 | |
| Ammonia Solution, Strong SCHEMBL20358007 | 0.77 | RAB9A (0.60) | ALDH1A1PKMKMT2ALMNAMEN1 | |
| SCHEMBL4978556 | 0.77 | ALDH1A1 (0.55) | ALDH1A1PKMKMT2ALMNAMEN1 | |
| SCHEMBL4978822 | 0.77 | ALDH1A1 (0.55) | ALDH1A1PKMKMT2ALMNAMEN1 | |
| SCHEMBL4978261 | 0.76 | PKM (0.56) | ALDH1A1PKMKMT2ALMNAMEN1 | |
| SCHEMBL20982763 | 0.75 | ALDH1A1 (0.72) | ALDH1A1PKMKMT2ALMNAMEN1 | |
| SCHEMBL209281 | 0.75 | ALDH1A1 (0.54) | ALDH1A1PKMKMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735432-B2 | N-(Heteroaryl)-1-heteroarylalky1-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2014-05-27 | — | — | US | disclosed |
| EP-1910335-B1 | N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI SA (FR) | 2013-11-06 | — | — | EP | disclosed |
| US-20130046095-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | DUBOIS LAURENT (FR) | 2013-02-21 | — | — | US | disclosed |
| US-8318775-B2 | N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2012-11-27 | — | — | US | disclosed |
| US-20100222368-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-09-02 | — | — | US | disclosed |
| US-7745467-B2 | N-(heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-06-29 | — | — | US | disclosed |
| US-20080146646-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2008-06-19 | — | — | US | disclosed |
| EP-1910335-A1 | N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | Sanofi-Aventis (FR) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007010144-A1 | N-(HETEROARYL)-1-HETEROARYLALKYL-1H-INDOLE-2-CARBOXAMIDE DERIVATIVES, PREPARATION AND USE THEREOF | SANOFI-AVENTIS (FR) | 2007-01-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222368-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | IDO1, IDO2, CNR2 | ALDH1A1 862/4885PKM 3215/4885KMT2A 1418/4885 |
| US-20130046095-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | IDO1, IDO2, CNR2 | ALDH1A1 862/4885PKM 3215/4885KMT2A 1418/4885 |
| US-20080146646-A1 | N-(Heteroaryl)-1-heteroarylalkyl-1H-indole-2-carboxamide derivatives, preparation and therapeutic use thereof | IDO1, IDO2, CNR2 | ALDH1A1 862/4885PKM 3215/4885KMT2A 1418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.